Johnson & Johnson (JNJ) recently revealed that updated findings from the Phase 3 MARIPOSA-2 study indicated significant benefits when combining RYBREVANT (amivantamab-vmjw) with chemotherapy for adult patients with previously treated non-small cell lung cancer (NSCLC) bearing epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations. The data also hint at a favorable trend toward improved overall survival compared to chemotherapy alone.During the second interim analysis, with a median follow-up of 18.1 months, it was observed that 50 percent of patients treated with the RYBREVANT and chemotherapy combination survived at the 18-month mark, in contrast to 40 percent who received only chemotherapy. Furthermore, the combination therapy demonstrated a noteworthy reduction in treatment discontinuation rates, with nearly five times as many patients remaining on therapy at the 18-month point (22 percent) compared to those on chemotherapy alone (4 percent). Additionally, patients receiving the combination experienced a 27 percent reduction in the risk of symptomatic progression.The RYBREVANT combination also significantly extended the time to subsequent therapy compared to chemotherapy alone, reducing the risk of second disease progression or death by 36 percent.In terms of safety, the profile of RYBREVANT combined with chemotherapy was consistent with the known profiles of each treatment individually. Permanent discontinuation of RYBREVANT due to adverse reactions occurred in 11 percent of patients.In August 2024, the European Commission granted approval for RYBREVANT plus chemotherapy as a treatment for patients with previously treated NSCLC with common EGFR mutations, based on the superior efficacy and safety profile demonstrated in the MARIPOSA-2 study.The material has been provided by InstaForex Company – www.instaforex.com
- Czech Retail Sales Growth Accelerates in August, Reaching 5.30% - October 8, 2024
- Czech Unemployment Rate Sees Slight Uptick in September - October 8, 2024
- France Sees Rise in Imports: August Figures Show a Notable Increase - October 8, 2024
